Literature DB >> 19430384

Effects of dietary cholesterol and simvastatin on cholesterol synthesis in Smith-Lemli-Opitz syndrome.

Yen-Ming Chan1, Louise S Merkens, William E Connor, Jean-Baptiste Roullet, Jennifer A Penfield, Julia M Jordan, Robert D Steiner, Peter J H Jones.   

Abstract

Deficient cholesterol and/or excessive 7-dehydrocholesterol (7-DHC) may be responsible for the pathology of Smith-Lemli-Opitz syndrome (SLOS). Both high-cholesterol diets given to ameliorate cholesterol deficiency while decreasing 7-DHC and cholesterol-enriched diets plus simvastatin to further decrease sterol synthesis have been used as potential therapies. However, the effect of dietary cholesterol and simvastatin on cholesterol synthesis in SLOS has not been reported. Twelve subjects with SLOS enrolled in the study: Nine had received a high cholesterol diet (HI) for 3 y and three were studied after 4 wk on a low cholesterol diet (LO). Cholesterol fractional synthesis rate (FSR) was measured after oral administration of deuterium oxide, using gas chromatography isotope ratio mass spectrometry. FSR was lower in HI compared with LO (HI: 1.46 +/- 0.62%/d; LO: 4.77 +/- 0.95%/d; p < 0.001). Three HI subjects were retested after 0.8 y taking simvastatin (HI + ST). Simvastatin tended to reduce FSR and significantly decreased (p < 0.01) plasma 7-DHC compared with cholesterol supplementation alone. The study demonstrates the utility of the deuterium incorporation method to understand the effect of therapeutic interventions in SLOS. The data suggest that dietary cholesterol supplementation reduces cholesterol synthesis in SLOS and further support the rationale for the combined treatment of SLOS with a cholesterol-enriched diet and simvastatin.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19430384      PMCID: PMC2780332          DOI: 10.1203/PDR.0b013e31819ea4eb

Source DB:  PubMed          Journal:  Pediatr Res        ISSN: 0031-3998            Impact factor:   3.756


  34 in total

Review 1.  The Smith-Lemli-Opitz syndrome.

Authors:  R I Kelley; R C Hennekam
Journal:  J Med Genet       Date:  2000-05       Impact factor: 6.318

2.  Cholesterol supplementation with egg yolk increases plasma cholesterol and decreases plasma 7-dehydrocholesterol in Smith-Lemli-Opitz syndrome.

Authors:  L M Linck; D S Lin; D Flavell; W E Connor; R D Steiner
Journal:  Am J Med Genet       Date:  2000-08-28

3.  Sterol balance in the Smith-Lemli-Opitz syndrome. Reduction in whole body cholesterol synthesis and normal bile acid production.

Authors:  R D Steiner; L M Linck; D P Flavell; D S Lin; W E Connor
Journal:  J Lipid Res       Date:  2000-09       Impact factor: 5.922

4.  Unesterified plant sterols and stanols lower LDL-cholesterol concentrations equivalently in hypercholesterolemic persons.

Authors:  Catherine A Vanstone; Mahmoud Raeini-Sarjaz; William E Parsons; Peter J H Jones
Journal:  Am J Clin Nutr       Date:  2002-12       Impact factor: 7.045

Review 5.  Smith-Lemli-Opitz syndrome: the first malformation syndrome associated with defective cholesterol synthesis.

Authors:  K P Battaile; R D Steiner
Journal:  Mol Genet Metab       Date:  2000 Sep-Oct       Impact factor: 4.797

6.  Efficacy and safety of atorvastatin in children and adolescents with familial hypercholesterolemia or severe hyperlipidemia: a multicenter, randomized, placebo-controlled trial.

Authors:  Brian W McCrindle; Leiv Ose; A David Marais
Journal:  J Pediatr       Date:  2003-07       Impact factor: 4.406

7.  Feedback inhibition of the cholesterol biosynthetic pathway in patients with Smith-Lemli-Opitz syndrome as demonstrated by urinary mevalonate excretion.

Authors:  Anuradha S Pappu; Robert D Steiner; Sonja L Connor; Donna P Flavell; Don S Lin; Lauren Hatcher; D Roger Illingworth; William E Connor
Journal:  J Lipid Res       Date:  2002-10       Impact factor: 5.922

8.  Cholesterol treatment forever? The first Scandinavian trial of cholesterol supplementation in the cholesterol-synthesis defect Smith-Lemli-Opitz syndrome.

Authors:  L Starck; A Lövgren-Sandblom; I Björkhem
Journal:  J Intern Med       Date:  2002-10       Impact factor: 8.989

9.  Early statin therapy restores endothelial function in children with familial hypercholesterolemia.

Authors:  Saskia de Jongh; Marc R Lilien; Jos op't Roodt; Erik S G Stroes; Henk D Bakker; John J P Kastelein
Journal:  J Am Coll Cardiol       Date:  2002-12-18       Impact factor: 24.094

Review 10.  Screening and treatment for lipid disorders in children and adolescents: systematic evidence review for the US Preventive Services Task Force.

Authors:  Elizabeth M Haney; Laurie Hoyt Huffman; Christina Bougatsos; Michele Freeman; Robert D Steiner; Heidi D Nelson
Journal:  Pediatrics       Date:  2007-07       Impact factor: 7.124

View more
  22 in total

Review 1.  Malformation syndromes caused by disorders of cholesterol synthesis.

Authors:  Forbes D Porter; Gail E Herman
Journal:  J Lipid Res       Date:  2010-10-07       Impact factor: 5.922

2.  In Memoriam: William E. Connor (1921-2009).

Authors:  Shailendra B Patel; Robert D Steiner
Journal:  J Lipid Res       Date:  2010-04       Impact factor: 5.922

3.  The Effect of Small Molecules on Sterol Homeostasis: Measuring 7-Dehydrocholesterol in Dhcr7-Deficient Neuro2a Cells and Human Fibroblasts.

Authors:  Zeljka Korade; Hye-Young H Kim; Keri A Tallman; Wei Liu; Katalin Koczok; Istvan Balogh; Libin Xu; Karoly Mirnics; Ned A Porter
Journal:  J Med Chem       Date:  2016-01-29       Impact factor: 7.446

4.  Endogenous B-ring oxysterols inhibit the Hedgehog component Smoothened in a manner distinct from cyclopamine or side-chain oxysterols.

Authors:  Navdar Sever; Randall K Mann; Libin Xu; William J Snell; Carmen I Hernandez-Lara; Ned A Porter; Philip A Beachy
Journal:  Proc Natl Acad Sci U S A       Date:  2016-05-09       Impact factor: 11.205

5.  7-Dehydrocholesterol-derived oxysterols and retinal degeneration in a rat model of Smith-Lemli-Opitz syndrome.

Authors:  Libin Xu; Lowell G Sheflin; Ned A Porter; Steven J Fliesler
Journal:  Biochim Biophys Acta       Date:  2012-03-09

Review 6.  Desmosterolosis-phenotypic and molecular characterization of a third case and review of the literature.

Authors:  Christian P Schaaf; Janet Koster; Panagiotis Katsonis; Lisa Kratz; Oleg A Shchelochkov; Fernando Scaglia; Richard I Kelley; Olivier Lichtarge; Hans R Waterham; Marwan Shinawi
Journal:  Am J Med Genet A       Date:  2011-06-10       Impact factor: 2.802

7.  Statins for Smith-Lemli-Opitz syndrome.

Authors:  Rami A Ballout; Simona Bianconi; Alicia Livinski; Yi-Ping Fu; Alan T Remaley; Forbes D Porter
Journal:  Cochrane Database Syst Rev       Date:  2020

8.  Comparison of the liquid-ordered bilayer phases containing cholesterol or 7-dehydrocholesterol in modeling Smith-Lemli-Opitz syndrome.

Authors:  Galya Staneva; Claude Chachaty; Claude Wolf; Peter J Quinn
Journal:  J Lipid Res       Date:  2010-02-10       Impact factor: 5.922

Review 9.  Pathogenesis-based therapies in ichthyoses.

Authors:  Joey E Lai-Cheong; Peter M Elias; Amy S Paller
Journal:  Dermatol Ther       Date:  2013 Jan-Feb       Impact factor: 2.851

Review 10.  Treatment of Smith-Lemli-Opitz syndrome and other sterol disorders.

Authors:  Melissa D Svoboda; Jill M Christie; Yasemen Eroglu; Kurt A Freeman; Robert D Steiner
Journal:  Am J Med Genet C Semin Med Genet       Date:  2012-10-05       Impact factor: 3.908

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.